Revolution Medicines (RVMD) Gains from Investment Securities (2023 - 2026)

Revolution Medicines' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $15.8 million for Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 747.31% year-over-year to $15.8 million in Q1 2026; TTM through Mar 2026 was $33.6 million, a 1275.53% increase from a year earlier, with the FY2025 full-year figure at $15.4 million, up 455.26% from the prior year.
• Gains from Investment Securities improved to $15.8 million in Q1 2026 per RVMD's latest filing, from $12.6 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $15.8 million in Q1 2026 and bottomed at -$3.9 million in Q1 2024.
• The 4-year median for Gains from Investment Securities is $406000.0 (2024), against an average of $2.7 million.
• Biggest YoY gain for Gains from Investment Securities was 5639.55% in 2025; the steepest drop was 53.35% in 2025.
• Year by year, Gains from Investment Securities stood at $115000.0 in 2023, then soared by 91.3% to $220000.0 in 2024, then soared by 5639.55% to $12.6 million in 2025, then gained by 25.03% to $15.8 million in 2026.
• Per Business Quant, the three latest RVMD Gains from Investment Securities figures stand at $15.8 million (Q1 2026), $12.6 million (Q4 2025), and $592000.0 (Q3 2025).